Asthma Spacers Market Report 2025 (Global Edition)

MARKET DYNAMICS: KEY DRIVERS

The increase in the prevalence of chronic respiratory conditions is fuelling the asthma spacers market growth

Chronic respiratory diseases, such as asthma and bronchitis, are the common non-communicable illnesses worldwide. Rise in air pollution , surge in geriatric population, and worsening lifestyle are key factors leading to growth in cases of asthma. For instance, in 2023, WHO mentioned the following facts, Noncommunicable diseases (NCDs) caused 41 million deaths annually, accounting for 74% of global deaths. Cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes account for over 80% of premature NCD deaths. Factors like tobacco use, inactivity, alcohol, unhealthy diets, and air pollution increase the risk. Detection, screening, treatment, and palliative care are crucial components of NCD response. http://  (https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases) In addition, surge in cases of chronic respiratory diseases is boosting the demand for therapeutic and management devices such as asthma spacers. Spacers allow for optimum wellness by ensuring efficient delivery of medication to the lungs. Their application reduces medication wastage, fosters better disease management and improves drug deposition. For instance, in 2020, Cipla Limited completed a Phase-3 clinical end-point study for fluticasone propionate and salmeterol inhalation powder (100/50 mcg), a generic version of GSK's Advair Diskus. The study, conducted over 15 months at over 100 US sites, enrolled 1400 asthma patients. Results showed that Cipla's fluticasone propionate and salmeterol inhalation powder is therapeutically equivalent to Advair Diskus100/50mcg, in accordance with regulatory recommendations and guidelines. No safety concerns were identified during the trials. Cipla's strong respiratory capabilities and wide range of drug-device combinations have established its position as a lung leader in India and other emerging markets. http://  (https://www.cipla.com/latest-respiratory-article/cipla-announces-successful-completion-phase-3-clinical-study-generic)

 

Restraint 

Unavailability of funding and investment for the product expansion and Product Design and Availability will hamper Asthma Spacers market growth

Given that there is now very little money available for the asthma spacer product expansion, more patients are unable to benefit from this cutting-edge medical technology. The manufacture and distribution of the asthma spacer product have been hampered by a lack of finance and investment, which has restricted its accessibility to a wider population. As a result, many people who have asthma are unable to benefit from this innovative medical technology For instance, in March 2023, The US Food and Drug Administration (FDA) has reported a nationwide shortage of albuterol, an asthma medication, which has been on its list since late October. The shortage, which affects the aerosolized solution used in nebulizers in hospitals, is primarily affecting hospital settings. The FDA has been working closely with manufacturers and supply chain partners to understand, mitigate, and prevent the impact of the shortage. The FDA has been tracking the shortage, and last month, generic drug manufacturer Akorn Pharmaceuticals filed for Chapter 7 bankruptcy and closed its US facilities, leaving Nephron Pharmaceuticals as the only remaining primary manufacturer of liquid albuterol. The FDA is working to address the shortage and is exploring all available regulatory levers to ensure supply. Local pharmacies are also concerned about the closure of Akorn facilities making it harder to stock albuterol. http://(https://abcnews.go.com/Health/nationwide-shortage-asthma-medication-albuterol-worsen/story?id=97708519)
Furthermore, market expansion may be impacted by asthma spacers' availability and design. There are several spacer alternatives available on the market, varying in terms of features, materials, and sizes. Although there are numerous options available, this diversity may also make it difficult for patients and medical professionals to choose the best spacer for their particular needs. Moreover, the potential for market growth may be hampered by the absence of established standards for spacer selection and restricted access to suitable spacers. 

Opportunities

Integration of new technologies facilitates the expansion of the asthma spacers market

Over the period the market will grow globally due to the integration of new technologies in the asthma spacers.  As a result treatment for asthma will be more convenient and effective because of the integration. For instance, in 2020, Propeller Health, a smart inhaler developer,  partnered with AstraZeneca's Symbicort to digitize asthma and COPD treatment. The cloud-based system uses electronic devices to track medication usage through a smartphone app, providing users with a clearer picture of disease control. Propeller's partnership expands its reach to about 90% of inhaled medicines for asthma and COPD in the U.S. Propeller's research shows that digitally tracking each puff from an inhaler can increase medication adherence, control asthma, and reduce hospital and emergency room visits. http://(https://propellerhealth.com/press/press-releases/propeller-health-receives-fda-clearance-to-connect-patients-using-the-symbicort-inhaler-to-its-digital-health-platform/) Furthermore, the addition of cutting-edge sensors and wireless connectivity allows for real-time medicine usage which gives patients and healthcare professionals insightful information. This improved functionality will also permit remote monitoring and personalized care. Patients can receive timely reminders and alerts for taking their prescriptions through real-time monitoring of drug usage. Additionally, medical professionals can monitor their patients' progress online and modify treatment regimens as needed, which lowers frequent in-person visits and improves overall efficiency in asthma management. For instance, in 2022, Teva Pharmaceuticals has released a study revealing that nearly one-third of asthma patients make 138 or more inhalations per year, indicating a risk of asthma exacerbation. The study suggests that digital inhalers can help healthcare professionals identify and address SABA reliever overuse, enabling clinical decision-making based on individual insights. The ProAir Digihaler, a smart inhaler for treating bronchospasm, is the first smart inhaler with built-in sensors that captures personal data, allowing patients to track and share their data with healthcare providers. http://(https://www.tevapharm.com/news-and-media/latest-news/teva-announces-new-findings-highlighting-potential-of-proair-digihaler-albuterol-sulfate-inhalation-p/)

Impact of COVID-19 on the Asthma Spacers Market

The COVID-19 crisis led the market for asthma spacers to expand even more quickly. For instance , Asthma deaths in the US have increased by over 17% from 3,524 in 2019 to 4,145 in 2020, the first significant increase in over 20 years, according to federal data from the Asthma and Allergy Foundation of America. The increase is "puzzling" for a disease that is largely manageable through various treatments. Rising temperatures, wildfires, and record flooding contribute to the increase in asthma cases. People of color with chronic respiratory conditions face additional threats, including more polluted air from industrial, agricultural, and residential sources. In addition, Acute respiratory disease syndrome (ARDS) has struck many patients, and the number of COVID-19 cases displaying respiratory symptoms has led to a sharp rise in the requirement for asthma spacers, due to which Asthma sufferers (PWAs) are also more susceptible to serious COVID-19-related infections. For instance, More recent reports in the United States have indicated that approximately 25% of young adults hospitalized with COVID-19 had a history of asthma, and among children 40% had some form of chronic lung disease (including asthma)”. Furthermore, the COVID-19 pandemic has significantly impacted asthma management, forcing clinicians to reconsider high-risk procedures like spirometry and nebuliser therapy. The use of commercial spacers with pressurised metered-dose inhalers is limited due to high costs and stock unavailability. Telemedicine has been promoted for patients' asthma control and monitoring. For instance, Malaysian pharmacists have introduced the respiratory Medication Therapy Adherence Clinic to improve patient health literacy and medication compliance. Telepharmacy offers a promising model for asthma education and pharmacovigilance. http://(https://www.nbcnews.com/health/health-news/asthma-deaths-rose-pandemic-climate-change-may-make-worse-rcna43798)
 

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The Global Asthma Spacers Market is witnessing significant growth in the near future.

In 2023, the Aerochamber segment accounted for noticeable share of global Asthma Spacers Market and is projected to experience significant growth in the near future.

The segment is expected to expand at the significant CAGR retaining position throughout the forecast period.

Some of the key companies AstraZeneca , Pari Gmbh(U.S.) and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.

Frequently Asked Questions (FAQs)